Antibodies drug delivery system

Uploaded on


  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads


Total Views
On Slideshare
From Embeds
Number of Embeds



Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

    No notes for slide


  • 4. INTRODUCTION  Antibodies are produced by a specialized group of cells called B-Lymphocytes. When an foreign antigen enters the body due immune response B-Lymphocytes develops into plasma cells and liberates antibodies or immunoglobulins of various types(Ig A, Ig D, Ig E, Ig G, Ig M). 4
  • 5. Classes of IgsIgG: IgG1 (66%), IgG2 (23%), IgG3 (7%) and IgG4 (4%) , blood and tissue liquidIgA: IgA1 (90%) and IgA2 (10%), external secretions(stomach, intestines, saliva, tears, etc.)IgM: 5-10% of total serum Ig [1.5mg/ml serumconc.]IgD: 1% of proteins in the plasma membranes of B-lymphocytes, function unknown [30µg/ml serumconc.] 0.2% of total serum IgIgE: 0.3µg/ml on the surface of plasma membrane ofmast cells, play a role in immediate hypersensitivityand denfense for parasite
  • 6. What are antibodies? An antibody is a protein used by the immune system to identify and neutralize foreign objects like bacteria and viruses. Each antibody recognizes a specific antigen unique to its target.Monoclonal antibodies (mAb) are antibodies that are identical because they were produced by one type of immune cell, all clones of a single parent cell.Polyclonal antibodies are antibodies that are derived from different cell lines. They differ in amino acid sequence.
  • 7. • Each Antigen has specific antigen determinants (epitopes) located on it. The antibodies have complementary determining regions (CDRs). These are mainly responsible for the antibody specificity.• Each antigen has several different epitopes on it. They are recognised by many different antibodies. All these antibodies thus produced act on the same antigen. Hence these are designated as polyclonal antibodies. 7
  • 8. • In general naturally produced antibodies are non- specific and heterogenous in nature. Hence there are several limitations in the use of polyclonal antibodies for therapeutic and diagnostic purposes.• Thus there is a need for producing monoclonal antibodies for different antigens. 8
  • 9. • 1890 Von Behring and kitasato discovered the serum of vaccinated persons contained certain substances, termed antibodies•  1900 Ehrlich proposed the ― side-chain theory‖• 1955 Jerne postulated natural selection theory. Frank Macfarlane Burnet expended.• Almost the same time, Porter isolated fragment of antigen binding (Fab) and fragment crystalline (Fc) from rabbit y-globulin.• 1964 Littlefield developed a way to isolate hybrid cells from 2 parent cell lines using the hypoxanthine-aminopterin-thymidine (HAT) selection media.• 1975 Kohler and Milstein provided the most outstanding proof of the clonal selection theory by fusion of normal and malignant cells• 1990 Milstein produced the first monoclonal antibodies.
  • 10.  Paul Ehrlich at the beginning of the 20th century theorized that a cell under threat grew additional side-chains to bind the toxin, and that these additional side chains broke off to become the antibodies that are circulated through the body. It was these antibodies that Ehrlich first described as "magic bullets" in search of toxins.
  • 11. Georges Köhler César Milstein, and Niels Kaj Jerne in1975 who shared the Nobel Prize in Physiology orMedicine in 1984 for the discovery hybridoma technology
  • 12. The structure of antibodies 
  • 13. Structure of MAb  13
  • 14. Antigen- antibody binding  14
  • 15. Types of mAbs designed• Murin source mAbs:: rodent mAbs with excellent  affinities and specificities, generated using conventional hybridoma technology. Clinical efficacy compromised by HAMA (human anti murine antibody) response, which lead to allergic or immune complex hypersensitivities.• Chimeric mAbs:: chimers combine the human constant regions with the intact rodent variable regions. Affinity and specificity unchanged. Also cause human antichimeric antibody response (30% murine resource)• Humanized mAbs:: contained only the CDRs of the rodent variable region grafted onto human Framework Regions [FR]
  • 16. Types of mAbs designed . . Human mAb :: three currently available approaches to the  production of human monoclonal antibodies are described. These include :- the hybridoma technique, based on the fusion of antibody- producing human B lymphocytes with either mouse or human myeloma or lymphoblastoid cells; the EBV immortalization technique, based on the use of Epstein- Barr virus (EBV) to immortalize antigen-specific human B lymphocytes; the EBV-hybridoma technique, based on a combination of the first two methods. The EBV-hybridoma system retains the advantageous features of the other two systems while overcoming their pitfalls and may be the current method of choice for producing human monoclonal antibodies with a defined specificity.
  • 17.
  • 18.  Hybridoma technology: In this B-Lymphocytes and myeloma cells are mixed together and exposed to PEG for a short period. The mixture contains hybridoma cells, myeloma cells and lymphocytes. This mixture is washed and cultured in HAT(hypoxanthine aminopterin and thymidine) medium for 7-10 days. only hybridoma cells remain in the mixture. 18
  • 19. Immunise Spleen Cell Myeloma Cell Line HAT sensitive FUSE Hybridoma HAT resistant SELECTStable hybrid myeloma producing desired antibody 19
  • 20. Nomenclature of mAbs 
  • 21.  Immunization Cell fusion Selection of hybridomas Screening the products Cloning and propagation Characterization and storage 21
  • 22.  Immunize an animal usually mouse by injecting with an appropriate antigen along with Freund’s complete or incomplete adjuvant. Adjuvants are non specific potentiators of specific immune responses. Injection of antigens at multiple sites are repeated several times for increased stimulation of antibodies. 3 days prior to killing of animal a final dose is given intravenously. Spleen is aseptically removed and disrupted by mechanical or enzymatic methods to release the cells. By density gradient centrifugation lymphocytes are separated from rest of the cells. 22
  • 23.  Lymphocytes are mixed with HGPRT deficient myeloma cells and is exposed to PEG for a short period. The mixture is then washed and kept in a fresh medium. The mixture contains hybridomas, free myeloma cells, and free lymphocytes. 23
  • 24. Dihydrofolate  Aminopterin TetrahydrofolatePrecursors Nucleotides---->DNA Hypoxanthine Thymidine 24
  • 25.  The above mixture is cultured in HAT medium for 7-10 days. Due to lack of HGPRT enzyme in myeloma cells, salvage pathway is not operative and aminopterin in HAT medium blocks the de novo synthesis of nucleotides. Hence free myeloma cells are dead. As the lymphocytes are short lived they also slowly dissappear. Only the hybridomas that receives HGPRT from lymphocytes are survived. Thus hybridomas are selected by using HAT medium Suspension is diluted so that each aliquot contains one cell each. These are cultured in regular culture medium, produced desired antibody. 25
  • 26. Conventional production of mAbsThe hybridoma technology:  spleen cells from immunized mice are fused with the murine myeloma cells.The several process had been developed at large scale.According to the different cell culture methods, it can calisifed into four fields1. Robottle cell culture process.1. Membrane binded cell culture process1. Microcarrier cell culture process1. Suspended cell culture process
  • 27.  Screening is done for antibody specificity. For this we need to test the culture medium from each hybridoma culture for desired antibody specificity. Common tests like ELISA and RIA are used for this. In these tests the antigens are coated to plastic plates. The antibodies specific to the antigens bind to the plates. The remaining are washed off. Thus the hybridomas producing desired antibodies are identified. The antibodies secreted by them are homogenous and specific and are referred as monoclonal antibodies. 27
  • 28.  The single hybrid cell producing the desired antibody are isolated and cloned. Usually two techniques are commonly employed for this a) Limiting dilution method: Suspension of hybridoma cells is serially diluted so the aliquot of each dilution is having one hybrid cell. This ensures that the antibody produced is monoclonal. b) Soft agar method: In this method the hybridoma cells are grown in soft agar. These form colonies and the colonies are monoclonal in nature. 28
  • 29.  Biochemical and biophysical characterization are made for desired specificity. It is important to note the monoclonal antibody is specific for which antigen MAbs must be characterized for their ability to withstand freezing and thawing. 29
  • 30.  Encapsulating the hybridoma cells in alginate gels and using a coating solution containing poly-lysine is employed. These gels allow the nutrients to enter in and antibodies to come out. Damon biotech and cell-tech companies are using this technique for commercial production of MAbs. They employ 100-litres fermenters to yield about 100g of MAbs in about 2 weeks period. 30
  • 31.  MAbs derived from mouse are murine derivatives. As they are not human origin, they show HAMA(human antimouse antibody) response. To overcome this we need to cleave the antibody into its respective Fc and Fab fragments. Fab fragments are less immunogenic and their smaller molecular size may facilitate penetration into tumor tissue and result in a longer half-life. Engineering is needed to reduce the immunogenicity. 31
  • 32.  Chimeric antibodies: Hence the murine antibodies are immunogenic to humans, the obvious solution for this is to clone a fully human antibody. But it has many problems like ethical clearance, difficult to culture, impossible to obtain many of the appropriate antibodies. To over come HAMA(human antimouse antibody) response, a chimeric antibody is prepared with Fc region of human IgG and Fab regions of murine origin by the use of DNA recombinant technology. 32
  • 33. V domainsMouse ChimericHuman C domains 33
  • 34.  Humanized antibodies: Though chimeric antibodies elicit less HAMA response than murine antibodies, they are still immunogenic due to their murine regions(30%) It is came to know that a small portion(CDR) of an antibody was actually responsible for antigen binding. By this humanized antibodies are prepared by recombinant DNA technology with majority of human antibody framework and CDR’s of murine antibody. Thus humanized antibodies are 95% homology with human antibodies. 34
  • 35. hypervariableMouse HumanisedHuman framework 35
  • 36.  Bispecific antibodies: These are specific to two types of antigens. They are constructed by r.DNA technology. Each arm is specific to one type of antigen. 36
  • 37.  Immunoconjugate: For MAb targeted drug delivery, a drug is bound covalently to an antibody that is chosen to target it to the desired site of action. Spacer is present between the antibody and the drug. Polymer may be present to increase the no. of drug molecules attached to the antibody. Drug is non-covalently incorporated into a liposome or microsphere to which the targeting antibody is bound to the surface—immunoliposome or immunomicrosphere resp. 37
  • 38.  Principle involved: As several classes of the drugs lack specificity for diseased cells, they show their action on other sites of action. Ex: cytotoxic action of chemotherapeutic agents is directed against any rapidly proliferating cell population. Hence drug targeting is required to overcome this problem. Targeting is classified into three categories: 1. Passive targeting 2. Physical targeting 3. Active targeting 38
  • 39.  It is the natural in-vivo distribution pattern of the drug delivery system. It is determined by the inherent properties of the carrier like hydrophobic and hydrophilic surface characteristics, particle size, surface charge, particle number. Ex: passive targeting of the lungs is made by modulating the size of the particles to >7µm passive targeting of the Reticuloendothelial system is made by modulating the size of the particles to 0.2- 7µm 39
  • 40.  In this some characteristics of the environment are utilized for the carrying of the drug to the specific site. Ex: thermal sensitive liposomes(local hyperthemia) magnetically responsive albumin microspheres (localized magnetic field) 40
  • 41.  Active targeting is usually done by cell-specific ligands. These are specific to specific cell types. But it is limited to small no. of tumor types. Hence MAb targeting is adopted for active targeting. MAb targeting is done by conjugating the drug antibody of the specific targeting type. Hence antibody drug conjugates are used as active targeting drug delivery systems. 41
  • 42.  Toxin conjugates (immunotoxins) EX: diphtheria toxin, Ricin have been conjugated to the tumor specific antibodies Ricin has two chains. Amoung these A-chain is cytotoxic and B-chain is non-specific. Hence B-chain is removed and the toxin is conjugated to tumor specific antibody. Thus we increase the specificity of the toxins by using MAbs as active drug targeting systems. 42
  • 43.  Drug immunoconjugates: Agents like chlorambucil, methotrexate and doxorubicin are conjugated with tumor specific antibodies. Ex: doxorubicin-BR96 immunoconjugate for Lewis antigen found on the surface of tumor cells. 43
  • 44.  They are homogenous in nature. They are specific to a particular antigen with a particular epitope. Ex:Rituximab (Rituxan®, anti-CD20) is a good example – this antibody is used for the treatment of lymphoma. 44
  • 45. mAbs Treatment For Cancer Cells ADEPT, antibody directed enzyme prodrug therapy; ADCC, antibody dependentcell-mediated cytotoxicity; CDC, complement dependent cytotoxicity; MAb,monoclonal antibody; scFv, single-chain Fv fragment.Carter P: Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer2001;1:118-129
  • 46. Strategy of a Direct or IndirectInduction of Apoptosis in TargetedCancer Cells 1. mAbs target growth factor receptors to exert a direct effect on the growth and survival of the cancer cells by antagonizing ligand-receptor signaling.1. mAbs can target to cell surface antigens and directly elicit apoptotic signaling.Dale L Ludwig, et. al. Oncogene(2003) 22, 9097-9106
  • 47. FDA Approval  The first approved mAbs was OKT-3 [1986], which is a murine IgGa2 protein to deplete T cells in patients with acute rejection of renal allotransplant. Until Feb 28, 2005, 18 mAbs were approved by FDA, which were applied in the treatment of organ transplant, Cancer, Asthma, Hematopoietic malignancies and psoriasis.Jancie, M Recheit, etal. Nature biotechnology, 2005, Sep,Vol. 23, No.9Stamatis-Nick C. J Allergy Clin. Immunol, Oct. 2005
  • 48. OKT3 Prevents acute rejection of kidney transplants Prevents autoimmune destruction of islet cells in type I Diabetes mellitus
  • 49.  Cell Depletion Rituxan, Campath (naked) Myelotarg (drug)  Zevalin, Bexxar (radioisotope) Blocking receptors Herceptin Attacking vasculature Avastin, Erbitux Vaccination against idiotype Panorex? 51
  • 50.  As they are specific to a particular antigen, they cannot distinguish molecule as a whole. Some times they cannot distinguish groups of different molecules. Ex:- presence of retro viruses as a part of mammalian chromosomes is not distinguished. Mice used in MAb production carry Adenovirus, Hepatic virus, Retrovirus, reovirus, cytomegalovirus, thymic virus. The presence of some of these viruses is detected in hybridomas. This poses a great danger since there is no guarantee for MAb produced is totally virus free. For this reason US food and drug administration insists that MAb for human use should be totally free from all pathogenic organisms including viruses. 52
  • 51. Latest NewsNorth Carolina-based  has established a joint PPDventure with Taijitu Biologics to develop andcommercialize a technology platform for thediscovery of first- and best-in-class monoclonalantibody therapies in collaboration with MABDiscovery GmbH in Munich. The joint venturewill provide drug discovery services based on thistechnology platform to global biopharmaceuticalcompanies, enabling them to discover best-in-classmonoclonal antibodies against both novel andvalidated targets.
  • 52.  Biotechnology by U. Satyanarayana Harpers Biochemistry 26th edition Carter P: Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118-129 Dale L Ludwig, et. al. Oncogene(2003) 22, 9097-9106 Jancie, M Recheit, etal. Nature biotechnology, 2005, Sep,Vol. 23, No.9 Stamatis-Nick C. J Allergy Clin. Immunol, Oct. 2005 54
  • 53. THANKU 55